

Chemotherapeutic Agents, chapter 38-43

- Antibacterial compounds (procaryotes)
- Antifungal compounds (eucarytotes)
- Antiparasitic agents (eucarytotes)

- Antiviral compounds

- Anticancer compounds

Different living organisms

Eucaryotes

Mono or polycellular
Cell nucleus; DNA
May have cell wall
sexual and / or asexual replication

Animals

Plants

Fungi


Protocista: - Protozoa
- Alga

Procaryotes

Bakteria:
Monocellular, no nucleus - DNA single strand,
cell wall, asex. replic.

Virus

RNA or DNA + protein coating (not really a cell)
Use other organisms ribosomes for protein synth



Antibacterial compounds, chapter 38(- antimycobacterials)

- Synthetic antibacterials (chemotherapeutica)**
- Antibiotics**

Antibiotics

Product from metabolism (natural product)

(also applies if compd is prepared synthetically,

or is a synthetic analog of a naturally occurring antibiotic/ semisynthetic compd)

Inhibit growth (bacteriostatic) or kill (bacteriocide) microorg.

Effective in low conc.

Antimicrobial chemotherapeutics: Antimicrobial comp \neq Antibiotics

G+ and G- bacteria

Grampositive bakterier:

F. eks.

Streptococcus


Staphylococcus

Bacillus - causes anthrax and gastroenteritis

Clostridium - causes botulism, tetanus, gas gangrene, and pseudomembranous colitis

Corynebacterium - causes diphtheria

Listeria - causes meningitis



The cell walls of gram-positive bacteria are made up of twenty times as much murein or peptidoglycan than gram-negative bacteria. These complex polymers of sugars and amino acids cross-link and layer the cell wall.


The thick outer matrix of peptidoglycan, teichoic acid, polysaccharides, and other proteins serve a number of purposes, including membrane transport regulation, cell expansion, and shape formation

Gramnegative bakterier:

F. eks.

Spirochetes - causes syphilis, lyme disease

Neisseria- causes meningococcus, gonorrhea



Gram-negative bacteria have a unique outer membrane, a thinner layer of peptidoglycan, and a periplasmic space between the cell wall and the membrane.


In the outer membrane, gram-negative bacteria have lipopolysaccharides (LPS), porin channels, and murein lipoprotein all of which gram-positive bacteria lack. The gram-negative outer membrane which contains LPS, an endotoxin, blocks antibiotics, dyes, and detergents protecting the sensitive inner membrane and cell wall.

Synthetic antibacterials (chemotherapeutica)

Antibacterial sulfonamides


Azo dyes

Bayer etc
Late 1800-century, ex.




Salvarsan

1. antisyphilis drug 1912




Screening of dyes as antibacterials


1932: **Prontocil** active against Streptococcus infection
no activity on bacterial cultures



1935: Prontocil metabolized (azoreductase) to **Sulfanilamid** *in vivo*




Modern sulfa drugs



R: Aryl or heteroaryl

Sulfonamides are acidic




Sulfanilamid
pKa 10.4

Neutral sulfonilamid low water sol.


Urine pH ca 6: Crystallization neutral form, kidney damage


Modern sulfa drugs pKa 5 – 7; better solubility



Sulfametoxazol

**Bactrim®, Trimetoprim-Sulfa® -
Urine infections
Combi. with trimethoprim**





Inhib. of folate reductase

Quinolones


Inhib DNA-synthesis; DNA-gyrase (prokaryoter) unwinding DNA before replic.

DNA-topoisomerase (humans), anticancer compds. ex. doxorubicin

Unique mechanism, no cross resistance


Broad spectrum: G+ and G- ; also mycobacteria, clamydia

Parent comp.
Nalidixic acid




Urinary tract infect. earlier
effect on Gram-negative bacteria (ex. *E. coli*)

Intramolek.
H-bond





pKa ca 5.5 - 6.5
(Benzoic acid pKa 4.2)

Moderne quinolones



Chelater with
Ca²⁺, Mg²⁺, Zn²⁺, Fe²⁺, Fe³⁺, Bi³⁺






Ciprofloksacin


Ciprox®, **Ciprofloxacin®**

Cilox®




Ofloksacin


Tarivid®




Levofloxacin, 2x active



Sparfloxacin



Trovafloxacin



Better effect on G+

Oxazolidones

Reg. Norge 2002,

1. antibact. drug with new mechanism of action in 35 years


Inhib. protein synthesis early

No cross resist.. G+ and some G-.


Resistant strains

Linesolid



Zyvoxid®





CH₃O, CH₃SO,
Aryl, Heteroaryl,
Metall Heterosykel



New drugs?







Antibiotics


β -Lactam-antibiotics

Lactam = cyclic amide


β -Laktam




Penicillins



β -Laktamase-inhibitors




Karbapenems




+ Cilastatin

Cefalosporines




Monobaktames




Penicillines

Gen. struct



β -lactam
(2S, 5R, 6R)




1-Aza-4-thiabicyclo[3.2.0]heptane

N

S

tot. 7 atoms in ring

X atoms




[x.y.z]alkane




tot no. of atoms

Mechanism


Inhib. cell wall synth. - peptidoglycane
 ≈ ala-ala




Peptidoglycane detail



Peptidoglycane synth. -cross linking




penicillin (≈ ala-ala) irreversible binding to trans peptidase
 Cross linking inhibited




Semi synthesis

two amide func.
Hydrolysis




R=Ph: Benzylpenicillin
R=OPh: Fenoksymetylpenicillin
from fermentation




Stability


Basic amide hydrol. - ring strain in β -lactame




Acidic hydrolysis
Alternative A




Acidic hydrolysis
Alternative B



Acidic hydrolysis
Alternative C




Structure acide stable penicillines



Semisynthetic, increased acid stability


Ampicillin

Pentrexyl®,




Amoxicillin

Amoxicillin®,




Piperacillin

Tazocin®





Pivampicillin

Pondocillin®,




Resistant strains




Larger R; effect on β -lactamase resistant bacteria (sterical hindrance)

Meticillin




Acid labile, last resort drug resist. strains

Kloksacillin Ekvacillin®





Dikloksacillin Diclocil®



Semisynthetic, Broad spectrum, Imines

Meticillinam


Selexid®



**No nucleophilic
carbonyl**


Pivmetecillinam

Selexid®




β -Lactamase Inhibitors


Combination with penicillines



Clavulanic acid




Tazobaktam




•Mechanism based irreversible enzyme inactivators

Suicide substrate - kcat inhibitors - Trojan horse inhib. - latent alkylating agent
 \approx Pro-drug, must be activated by the enzyme

Clavulanic acid irreversibly inhibits β -lactamase




Carbapenems / Carbapenins



Tienamycin from *Streptomyces cattleya* 1976

Broad spectrum



Not substr. for β -lactamase




Labile, acidic and basic media

Cleaved *in vivo* av DHP-I (dehydropeptidase I)

Imipenem + cilastan
Tienam®





Meropenem
Meronom®



2. Gen.
Not cleaved by DHP-1


Cephalosporins

Cefalosporin C from *Cephalosporium acremonium* 1945




6- membered ring; Less ring strain than penicillins

Subst in 3-pos., important for hydrolytic stability



Good leaving group


Metabolism




Inactive lactone

Isolation from *Cephalosporium sp*

or semisynth from **7-aminocephalosporic acid (7-ACA)**




Semisynth from penicillins




**1. generation: Relatively broad spectrum (G+, some G-)
Cleaved by β -Lactamase**

Cephalexin
Cefalexin® Keflex®




Relatively diff. to hydrolyze
Only oral Ceph.

Cefalotin
Cefalotin® Keflin®



**2. generation: More broad spectrum
Not cleaved by β -Lactamase**


Cefoxitin
Mefoxitin®



Increased stability
compared to cephalotin

Steric hindrance β -L

Cefuroxim
Cefuroxim® Zinacef®




Syn isomer, steric hindrance β -L
Anti cleaved by β -L

3. generation: **Very broad spectrum, also *Pseudomonas sp***
Not cleaved by β -Lactamase
Acid labile

Cefotaxim

Cefotaxime®


Claforan®



Ceftazidim

Fortum®



Good leaving group
 Steric hindrance
 G-



Oral 3. gen (not in N):


Ceftriaxon

Rohephalin®




R: -H, -CH=CH₂, -CH₂OCH₃

Monobactams




Only 4 membered ring

From **Sulfacetin**;
weak antibacterial
Not substrate for β -lactamase



Aztreonam



Azactam®



Mer stabil enn Sulfacetin
Bare effekt på G-


Aminoglycosides


- Broad spectrum
- Toxic
- Inhib. protein synthesis
- ≈No absorb. from GI, local treatment infect. GI tract.
- Systemic infections – parenteral adm.



- Basic, water soluble salts phys. pH
- -Glykosides (= acetals) stabile acidic media because of protonated amino subst.

Bind to
mRNA read wrong
Transloc. blocked





➤ **First aminoglyc.: Streptomycin (ca 1944) from *Streptomyces griseus***

➤ **First antituberculosis drug.**


Streptomycin ➤ **Toxic!**

Neomycin

Streptomyces fradia (1949).

Maxitrol®[®], eyedrops


Less tox. than streptomycin



Gentamicin

Garamycin®

From *Micromonospora purpurea*.




R = R' = -CH₃: **Gentamicin C₁**
 R = CH₃, R' = -H: **Gentamicin C₂**
 R = R' = -H: **Gentamicin C_{1a}**

Netilmicin

Netilyn® injek.

Semisynth from Sisomicin


(*Micromonospora inyoensis*)



Tobramycin

Nebcina®[®] Tobi®[®], Tobrex

Streptomyces tenebrarius.




Lincomycines

- Sulfur cont. antibiotics from *Streptomyces lincolnensis*;
- Naturally occurring: Linkomycin (not in N), more active semisynth der.
- Inhib protein synth, binds to 50S part of ribosome

Klindamycin

Dalactin® Dalactin® Clindamycin®.


Semisynth from linkomycin




R= H, R'=Cl: *Klindamycin*

R=OH, R'=H: *Linkomycin*,

Tetracyclines




Tetracyclines: Gen. struct. (reg. in N.)



Naftacene

- Mechanism: Binds to 30S part of ribosome, inhibits protein synth.; complexing Mg_{2+} involved.
- Binds also to 30S-rib. mammals, but bacteria cells also have active transport mech. for T uptake.
- The most broad spectrum antibiotic known to date.
- Bakteriostatic, not baktericid.
- Attacks natural bacteria flora in GI tract (oportunistic *candida* infect.)


Chelate




Chelate: Chelos = Claw, Klo (greek)

Met^{n+} Ca^{2+} (milk)
 Fe^{n+} (iron prep.)
 Al^{3+} (antacida.)

Acid - Base prop.




Zwitter ion (high water sol.)
 neutral pH




Stability; acid / base


pH 2 - 6: Epimerisation C-4




pH ≤ 2: Dehydratisation; Aromatisation C-ring (R₆=OH)



pH ≥ 7.5: Rearrangement to isotetracyclines (R₆=OH)




	R ₅	R ₆	R ₂
Tetracycline	-H	-OH	-H
Oxytetracycline	-OH	-OH	-H
Doxycycline	-OH	-H	-H
Lymecycline	-H	-OH	-CH ₂ NHCH ₂ NH(CH ₂) ₄ CH(NH ₂)CO ₂ H



Tetracyclin

Isolation from *Streptomyces* sp,
Semisynth from chlorotetracycline more effective
(low bioavailability)




Klortetracyclin
fra fermenter. av *Streptomyces* arter

Tetracyclin

Lymecyclin

More water sol., pro-drug.
Semisynth from tetracycline



Lymecyclin

Tetracyclin


Lysin

Doxycyclin


Not OH i 6-pos. More stable in water solution (also mixture).

Longer $t_{1/2}$, good oral absorb.

Semisynth oxytetracyclin.



Makrolides




- Isolated from soil-bacteria, *Streptomyces* sp.
- Relatively narrow spectrum, mainly G+. Low tox.
- Binds to 50S part of ribosome, inhib. Protein synth.


Structure / Activity:

- Macrolaktone (14-16-ring, smaller than antimycotic polyenes)
- Keto function
- No unsat. in lactone ring (spiramycin - dien) ≠ an timycotic polyenes
- Amino sugar

Erytromycin




Ester hydrol.
in vivo




Erytromycin ethylsuccinate
Pro-drug (masks bad tast)


Degradation acidic media



Spiro-
forbindelse




Klaritromycin



Increased stability acidic media
No intramolec. hemikatalisation

Increased stabil., bioavailability,
less side effects
Somewhat more broad spectrum


Azitromycin



Increased stability acidic media
No intramolec. hemikatalisation

Increased stabil., bioavail.
More active G- less active G+


Telitromycin



Increased stability acidic media
No intramolec. hemikatalisation
Improved ribosome binding, less resistance
Increased ribosome affinity

In N. 2002. Ketolide.

Spiramycin





Isolated *Streptomyces ambofaciens*.
G+.


R= H: Spiramycin I
R=COCH₃: Spiramycin II
R=COCH₂CH₃: Spiramycin III

Polypeptides

- Low oral avail.; local admin. or. infusion/injektion.
- Often high tox (kidneys).
- D-amino acids and other rare AA.




Vancomycin



Isol. *Streptomyces orientalis* (= *Amycolatopsis orientalis*).
 G+bacteria, *Neisseria* sp (G-).
 Inhib. Synth of mucopeptide polymer in cell wall.
 No oral uptake,
 Minimal degrad. In Gi, local treatment GI infect.
 Rel. tox., little resistance
 Severe infections few other alternatives

Teicoplanin



Isol. *Actinoplanes teichomyceticus*.

Only G+.

Mech as vanoc.m..

More lipid sol. than vancomycin, better distrib. In fat tissue

Little resistance tox. Less than vancomycin;

Severe infect., few alternatives

Bacitracin

Isol. *Bacillus subtilis*.

Mixt of struct


(Bacitracin A, A1, B, C, D, E, F1, F2, F3 and G)

Bacitracin A main comp. Bacimycin.

Mainly G+.


Inhib. Synth. mukopeptide in cell wall.

Requires Zn²⁺ for activity




Colistin (Polymyxin E₁)

Polymyxin B





Others

Chloroamfenikol



- Isolated from *Streptomyces venezuelae* (1947), later found in several microorg.
- Broad spectrum. Inhib. Protein synth., mech. Not fully understood.
- Rel. tox. (damage bone marrow – anemia, leukemia), seldom used systemically.
- Simple structure – total synthesis.

Fusidic acid



- Narrow spectrum: G+; *Staphylococcus aureus*, *Corynebacteria*, *Streptococcus* sp. (weak effect).
- Inhib. Protein synth.
- No cross resist.